- Genevant pens $303M biobucks pact with Takeda, aiming at rare liver diseases using gene therapy FierceBiotech
- Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases Business Wire
- View Full coverage on Google News